Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-11 00:42:24 UTC - SOMEWHAT_HELPFUL

Rated by Participant: 992AEC7364C532D43620236BAFC4A60CFF8E5FB7B909C2479ECB815AC346754D
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 992AEC7364C532D43620236BAFC4A60CFF8E5FB7B909C2479ECB815AC346754D
createdAtMillis - 1689036144617
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - SOMEWHAT_HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 1
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 1
ratingsId - 1677803233077522432992AEC7364C532D43620236BAFC4A60CFF8E5FB7B909C2479ECB815AC346754D